- Home
- DALN vs SCYX Comparison
DALN vs SCYX Comparison
Compare DALN & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DALN
- SCYX
- Stock Information
- Founded
- DALN 1954
- SCYX 1999
- Country
- DALN United States
- SCYX United States
- Employees
- DALN N/A
- SCYX N/A
- Industry
- DALN Newspapers/Magazines
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- DALN Consumer Discretionary
- SCYX Health Care
- Exchange
- DALN Nasdaq
- SCYX Nasdaq
- Market Cap
- DALN 33.9M
- SCYX 40.6M
- IPO Year
- DALN 2008
- SCYX 2014
- Fundamental
- Price
- DALN $6.20
- SCYX $1.07
- Analyst Decision
- DALN
- SCYX Buy
- Analyst Count
- DALN 0
- SCYX 1
- Target Price
- DALN N/A
- SCYX N/A
- AVG Volume (30 Days)
- DALN 41.5K
- SCYX 164.6K
- Earning Date
- DALN 03-05-2025
- SCYX 03-27-2025
- Dividend Yield
- DALN N/A
- SCYX N/A
- EPS Growth
- DALN N/A
- SCYX N/A
- EPS
- DALN N/A
- SCYX N/A
- Revenue
- DALN $128,286,000.00
- SCYX $8,566,000.00
- Revenue This Year
- DALN N/A
- SCYX N/A
- Revenue Next Year
- DALN N/A
- SCYX $365.06
- P/E Ratio
- DALN N/A
- SCYX N/A
- Revenue Growth
- DALN N/A
- SCYX N/A
- 52 Week Low
- DALN $2.98
- SCYX $0.90
- 52 Week High
- DALN $7.86
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- DALN 44.32
- SCYX 43.42
- Support Level
- DALN $5.84
- SCYX $1.06
- Resistance Level
- DALN $6.65
- SCYX $1.18
- Average True Range (ATR)
- DALN 0.41
- SCYX 0.07
- MACD
- DALN -0.03
- SCYX -0.00
- Stochastic Oscillator
- DALN 28.52
- SCYX 22.22
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.